Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Q1 FY2014 Earnings Presentation
12 slides from Immutep's earnings presentation, Nov 7, 2013
Slide 1: 1st quarter results for FY 2014 (period ended 30 September 2013)
1% quarter results for FY 2014 (period ended 30 September 2013) Supplemental information to management discussion November 7, 2013 ‘ASX:PRR; NASDAQ:PBMD; ISIN:US7415482034 ® PRIMA BIOMED
Slide 2: Important Notice
1st quarter results for FY 2014 (period ended 30 September 2013) Supplemental information to management discussion November 7, 2013 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 PRIMABIOMED1 Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 00
Slide 3: Termination of Oncothyreon Agreements
Termination of Oncothyreon Agreements + License and Development Agreement (and subsequent amendments thereto) terminated as of October 2, 2013 * Termination clarifies that Prima has no ongoing obligations to Oncothyreon related to mucin 1 technology * If CVac would be approved for sale in the United
Slide 4: Neopharm License
Termination of Oncothyreon Agreements • License and Development Agreement (and subsequent amendments thereto) terminated as of October 2, 2013 • Termination clarifies that Prima has no ongoing obligations to Oncothyreon related to mucin 1 technology • If CVac would be approved for sale in the United
Slide 5: CVac clinical development
CVac clinical development CAN-003 phase 2 top-line data reported September 18, 2013 Further analysis and updated data to be presented at Society for Immunotherapy of Cancer meeting on November 8, 2013 (poster presentation by Dr. Sharron Gargosky) Summary of outcomes on the four CAN-003 objectives: —
Slide 6: CVac in second remission ovarian cancer
CVac clinical development CAN-003 phase 2 top-line data reported September 18, 2013 Further analysis and updated data to be presented at Society for Immunotherapy of Cancer meeting on November 8, 2013 (poster presentation by Dr. Sharron Gargosky) Summary of outcomes on the four CAN-003 objectives: –
Slide 7: CVac clinical trial design considerations
CVac clinical trial design considerations — Strong PFS signal in second remission epithelial ovarian cancer patient population = Positive mucin 1-specific T cell response in CVac treated patients — Importance of Overall Survival as primary endpoint: * Based on available reported data in cancer immun
Slide 8: CAN-004 ovarian cancer protocol amendments
CVac clinical trial design considerations – Strong PFS signal in second remission epithelial ovarian cancer patient population – Positive mucin 1-specific T cell response in CVac treated patients – Importance of Overall Survival as primary endpoint: • Based on available reported data in cancer immun
Slide 9: CAN-301 pilot pancreatic cancer trial
CAN-301 pilot pancreatic cancer trial > 40 resected pancreatic cancer patients > Single-arm pilot trial > Endpoints: + Overall survival + Immune response + Safety Goal -> data to add value to the CVac franchise & drive go/no-go decision on further clinical trials in pancreatic cancer & PRIMA BIOMED
Slide 10: Financial results for 1st quarter FY 2014
CAN-301 pilot pancreatic cancer trial 40 resected pancreatic cancer patients Single-arm pilot trial Endpoints: • Overall survival • Immune response • Safety Goal -> data to add value to the CVac franchise & drive go/no-go decision on further clinical trials in pancreatic cancer PRIMA BIOMED 9 Financ
Slide 11: American Depository Receipt Program
American Depository Receipt Program 1m Total ADRs outstanding Net issued/canceled ADRS for the month Jul3 Aug-13 Sep-13 oct13 ‘ata provided from BNY Mellons of November 4, 2013, n & PRIMA BIOMED
Slide 12: Core business objectives & outlook
American Depository Receipt Program 2.5 2 Total ADRs outstanding 1.5 Millions Net issued/canceled ADRs 1 for the month 0.5 0 Jul-13 Aug-13 Sep-13 Oct-13 Data provided from BNY Mellon as of November 4, 2013 PRIMA BIOMED 11 Core business objectives & outlook 1. Bring CVac to clear clinical proof of co